濮阳东方医院治早泄口碑很好价格低濮阳东方男科医院收费低,濮阳东方妇科医院治病不贵,濮阳东方医院男科治阳痿评价比较高,濮阳东方医院割包皮价格,濮阳东方男科医院割包皮非常好,濮阳东方医院割包皮口碑怎么样,濮阳东方医院男科看早泄怎么样

JOHANNESBURG, March 8 (Xinhua) -- In order to combat piracy and to improve maritime safety, South African authorities have begun using a sophisticated navigation satellite system, it was announced on Tuesday.Piracy, especially by Somalis, has been increasing along Africa east coast in recent years. The South African Press Association (SAPA) reported on Tuesday that Karl Otto, head of the South African Maritime Safety Authority (SAMSA) announced the surveillance tool at a conference in Durban.Called Long Range Identification and Tracking (LRIT), the system monitors and tracks vessels in waters south of the equator.Otto said the introduction of the LRIT followed concerns over the safety of seafarers, the safety standards of ships within South African waters.Otto said there were high levels of cargo at risk, such as fuels and oils.He said reasons for installing the system included the number of shipwrecks along the South African coast, and the threat of pollution of the marine environment by ships."It also serves as a mechanism to prevent piracy."Otto said the satellite system has the capacity to identify and track vessels up to 1,000 nautical miles (1,850 km) from the South African coastline as well as South African-flagged vessels anywhere in the world."This is a revolutionary development in the security of our seas," he said.SAMSA was determined to protect South Africa's seafarers, its coastline and the marine environment, Otto said.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

You can think of NASA's Discovery program as a sort of outer-space American Idol: every few years the agency invites scientists to propose unmanned planetary missions. The projects have to address some sort of fundamental science question, and (this is the tough part) they have to be relatively cheap to pull off — say, half a billion dollars or so. Then the proposals go through a grueling competition before judges who aren't as nasty as Simon Cowell but who are every bit as tough. The one left standing at the end gets the equivalent of a recording contract: NASA supplies the funding and the launch vehicle, and away the winner goes — to orbit Mercury, as the Messenger spacecraft is doing right now; or to rendezvous with a couple of asteroids, as the Dawn mission will start doing this July; or to smash into a comet on purpose, a feat achieved by Deep Impact in 2005, a mission not to be confused with the movie of the same name. Now it's time for the next contenders. NASA has just announced that the first round of the latest Discovery competition is over, with three entries out of 28 moving on to the finals. They are, in increasing distance from Earth: the Geophysical Monitoring Station (GEMS) lander, which would use seismometers to study the interior of Mars; the Comet Hopper, which would do just that, leaping from place to place across the surface of Comet 46P/Wirtanen to see how different parts of the tumbling body react to heating by the sun; and the Titan Mare Explorer (TiME), which would plop into a sea of liquid hydrocarbons on Saturn's moon Titan — the first oceangoing vessel ever to set sail on another world. If you had to come up with a theme that ties all three missions together, it would be "origins." The Titan explorer, for example, will be studying a place that — in a crude way, at least — resembles the early planet Earth at a time when life arose here. Titan, with a thick atmosphere and a bizarro-world form of weather featuring toxic winds and hydrocarbon rain, is home to a mix of complex chemistry, complete with organic molecules. The oceans provide a medium in which the molecules can move around and interact with each other. It's even conceivable, though clearly a long shot, that some form of microscopic life already exists on this frigid moon. The Mars lander, by contrast, would visit a place where the seas — plain water in this case — vanished long ago. But the mission of GEMS goes far deeper than that. By analyzing Marsquakes on the Red Planet, GEMS will try to get a handle on what the interior of Mars is like. Scientists don't currently know whether the planet's core is liquid, like Earth's, or solid, or some mushy consistency in between. It all depends on how efficiently Mars has cooled since it formed 4.5 billion years ago, and that depends in turn on the planet's internal structure. "That's the mission," says Bruce Banerdt, of NASA's Jet Propulsion Laboratory, the lead scientist for GEMS. "We want to understand how Mars was built." Along with sensitive seismographic equipment, GEMS will drill down about 20 ft. (6 m) with a thermometer-equipped probe, trying to figure out how quickly the temperature rises with depth. "That will let us extrapolate all the way down to the center," Banerdt says, "which will tell us how fast Mars is cooling."

BEIJING, Feb. 11 (Xinhua) -- China's foreign exchange regulator said Friday it did not suffer any losses from its investment in Fannie Mae and Freddie Mac bonds, adding that media reports of up to 450 billion U.S. dollars of losses were "groundless.""Up until now, the capital and interest repayments of Fannie Mae and Freddie Mac bonds is normal, and no losses have incurred," The State Administration of Foreign Exchange (SAFE) said on its website.Annual yields of the bonds were around 6 percent between 2008 and 2010, the SAFE said.The regulator, which oversees China's more than 2 trillion U.S. dollars of foreign exchange reserve, also clarifies it had not bought any stocks of the two troubled mortgage companies.UPI reported on Friday that the Obama Administration will propose phasing out the two mortgage giants after rescuing them, which is part of a U.S. Treasury Department white paper to Congress that lays out three ways of cutting government support to the 10.6 trillion U.S. dollars mortgage market.

HONG KONG, March 18 (Xinhua) -- After over a year's efforts, scientists from Shanghai and Hong Kong announced on Friday that they have completed the whole genomic sequencing work of Isaria cicada, a rare herb highly valued in traditional Chinese medicine, which will help facilitate its further development in medical and nutrition fields.It is the first time that the whole genomic sequence of Isaria cicada has been released, said the scientists from Shanghai Institute of Bio-Asia Life Science and the Hong Kong University of Science and Technology (HKUST), who participated in the research.The result was announced at the International Biomedical Scientists and Biotechnology Forum 2011 held in the day at the Hong Kong Science Park.According to the result, the genomic size of Isaria cicada, a medicine traditionally used to treat children's diseases, is about one eightieth of human genome, containing about 16,000 genes.The tests that had been done proved that Isaria cicada, with many high-quality genes not recognized or used by human beings yet, has been deeply involved in important life processes like metabolism, providing new ways for further development of Isaria cicad in bio-medical area, said a scientist from HKUST.The genome map will also help accelerate the artificial cultivation of Isaria cicada, enhancing its medicine and nutrition value and making it available in a larger market, according to the scientist.